MYO7A_HUMAN,L247P,0.142,-,-,-
MYO7A_HUMAN,D248S,0.660,Gain of Allosteric site at R250 (Pr = 0.28 | P = 3.7e-03); Altered Metal binding (Pr = 0.27 | P = 7.7e-03); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.02), ELME000146|PS00005|PS00007,-
MYO7A_HUMAN,R250A,0.938,Loss of Allosteric site at R250 (Pr = 0.32 | P = 2.4e-03); Altered Metal binding (Pr = 0.30 | P = 5.3e-03); Loss of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), PS00007,-
MYO7A_HUMAN,V254I,0.299,-,-,-
MYO7A_HUMAN,V254L,0.608,Altered Metal binding (Pr = 0.28 | P = 5.9e-03); Loss of Allosteric site at Y256 (Pr = 0.26 | P = 0.01); Loss of Catalytic site at Y256 (Pr = 0.09 | P = 0.04), ELME000020|ELME000120,-
MYO7A_HUMAN,M258G,0.903,Altered Metal binding (Pr = 0.29 | P = 6.1e-03); Gain of Allosteric site at F255 (Pr = 0.29 | P = 2.4e-03); Gain of Catalytic site at Y256 (Pr = 0.15 | P = 0.02), ELME000020|ELME000120|ELME000182,-
MYO7A_HUMAN,E260P,0.533,Loss of Helix (Pr = 0.27 | P = 0.03); Gain of Allosteric site at Y256 (Pr = 0.27 | P = 4.5e-03); Gain of Catalytic site at Y256 (Pr = 0.10 | P = 0.04); Altered Metal binding (Pr = 0.08 | P = 0.02), ELME000239,-
MYO7A_HUMAN,G261S,0.598,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Allosteric site at Y256 (Pr = 0.25 | P = 0.01); Gain of Catalytic site at Y256 (Pr = 0.10 | P = 0.04); Altered Metal binding (Pr = 0.09 | P = 0.01), ELME000064|ELME000336|PS00006,-
MYO7A_HUMAN,S263G,0.181,-,-,-
MYO7A_HUMAN,E264Q,0.114,-,-,-
MYO7A_HUMAN,D265Q,0.293,-,-,-
MYO7A_HUMAN,K267L,0.517,Loss of B-factor (Pr = 0.30 | P = 7.7e-03); Loss of Methylation at K268 (Pr = 0.10 | P = 0.05), None,-
MYO7A_HUMAN,K268Q,0.236,-,-,-
MYO7A_HUMAN,Q274E,0.092,-,-,-
MYO7A_HUMAN,D277E,0.328,-,-,-
MYO7A_HUMAN,T288I,0.278,-,-,-
MYO7A_HUMAN,N300S,0.181,-,-,-
MYO7A_HUMAN,S351C,0.384,-,-,-
MYO7A_HUMAN,S357T,0.135,-,-,-
MYO7A_HUMAN,P364R,0.182,-,-,-
MYO7A_HUMAN,S423P,0.400,-,-,-
MYO7A_HUMAN,N443K,0.896,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Allosteric site at F439 (Pr = 0.25 | P = 9.7e-03); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000193,-
MYO7A_HUMAN,A445S,0.171,-,-,-
MYO7A_HUMAN,S481T,0.180,-,-,-
MYO7A_HUMAN,A495T,0.690,Altered Metal binding (Pr = 0.26 | P = 7.9e-03); Loss of Allosteric site at N492 (Pr = 0.26 | P = 0.01); Gain of Catalytic site at N492 (Pr = 0.14 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), None,-
MYO7A_HUMAN,N501S,0.257,-,-,-
MYO7A_HUMAN,I510L,0.559,Loss of Strand (Pr = 0.26 | P = 0.04); Gain of Allosteric site at E513 (Pr = 0.19 | P = 0.05); Altered Metal binding (Pr = 0.17 | P = 0.03), ELME000333|PS00006,-
MYO7A_HUMAN,N529W,0.756,, ELME000202,-
MYO7A_HUMAN,L534V,0.114,-,-,-
MYO7A_HUMAN,L534Y,0.280,-,-,-
MYO7A_HUMAN,A536M,0.210,-,-,-
MYO7A_HUMAN,A536T,0.080,-,-,-
MYO7A_HUMAN,Y538S,0.773,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Ordered interface (Pr = 0.34 | P = 2.8e-03); Altered DNA binding (Pr = 0.21 | P = 0.02); Gain of GPI-anchor amidation at N543 (Pr = 0.01 | P = 0.03), ELME000081|ELME000083|ELME000182,-
MYO7A_HUMAN,T562S,0.150,-,-,-
MYO7A_HUMAN,R585W,0.338,-,-,-
MYO7A_HUMAN,T603R,0.728,Gain of ADP-ribosylation at T603 (Pr = 0.24 | P = 0.01); Gain of Phosphorylation at S607 (Pr = 0.23 | P = 0.05), ELME000012|ELME000053|ELME000101|ELME000102|ELME000108|ELME000271|ELME000278|PS00005,-
MYO7A_HUMAN,L610M,0.387,-,-,-
MYO7A_HUMAN,A627G,0.322,-,-,-
MYO7A_HUMAN,R669H,0.605,Altered Ordered interface (Pr = 0.35 | P = 5.0e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.24 | P = 1.0e-02); Altered Metal binding (Pr = 0.10 | P = 0.05); Gain of Catalytic site at Y672 (Pr = 0.09 | P = 0.05), ELME000101|ELME000102|ELME000108,-
MYO7A_HUMAN,L689Q,0.840,Gain of Strand (Pr = 0.27 | P = 0.02); Loss of Allosteric site at Y685 (Pr = 0.22 | P = 0.03), ELME000106|ELME000146|ELME000149|ELME000155|ELME000167|ELME000231,-
MYO7A_HUMAN,A695V,0.439,-,-,-
MYO7A_HUMAN,K697Q,0.365,-,-,-
MYO7A_HUMAN,G699E,0.228,-,-,-
MYO7A_HUMAN,L701V,0.407,-,-,-
MYO7A_HUMAN,R707P,0.673,, ELME000062,-
MYO7A_HUMAN,A711T,0.135,-,-,-
MYO7A_HUMAN,H716Y,0.429,-,-,-
MYO7A_HUMAN,I726V,0.570,Gain of Strand (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.02), ELME000146,-
MYO7A_HUMAN,D730R,0.944,Altered Metal binding (Pr = 0.30 | P = 4.3e-03); Gain of Helix (Pr = 0.27 | P = 0.05); Altered DNA binding (Pr = 0.16 | P = 0.04), ELME000100|ELME000108|ELME000233|ELME000326,-
MYO7A_HUMAN,H731R,0.798,Altered Metal binding (Pr = 0.36 | P = 1.9e-03); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000149|ELME000233,-
MYO7A_HUMAN,D733G,0.860,Altered Metal binding (Pr = 0.30 | P = 4.1e-03), None,-
MYO7A_HUMAN,M734T,0.628,Altered Metal binding (Pr = 0.26 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Altered Stability (Pr = 0.14 | P = 0.02), ELME000064|ELME000220|ELME000335|PS00006,-
MYO7A_HUMAN,L736A,0.898,Altered Metal binding (Pr = 0.27 | P = 8.9e-03); Altered Stability (Pr = 0.11 | P = 0.03), ELME000047|ELME000333,-
MYO7A_HUMAN,V738C,0.352,-,-,-
MYO7A_HUMAN,K742P,0.770,Gain of Allosteric site at R740 (Pr = 0.19 | P = 0.05), ELME000146|ELME000173,-
MYO7A_HUMAN,K766R,0.174,-,-,-
MYO7A_HUMAN,N769S,0.099,-,-,-
MYO7A_HUMAN,A770S,0.291,-,-,-
MYO7A_HUMAN,L773V,0.125,-,-,-
MYO7A_HUMAN,R776K,0.378,-,-,-
MYO7A_HUMAN,H781Y,0.410,-,-,-
MYO7A_HUMAN,H801F,0.387,-,-,-
MYO7A_HUMAN,R802S,0.869,Altered Disordered interface (Pr = 0.46 | P = 4.1e-03); Altered DNA binding (Pr = 0.27 | P = 6.5e-03); Altered Coiled coil (Pr = 0.12 | P = 0.04), ELME000239|ELME000336|PS00005,-
MYO7A_HUMAN,R804Q,0.278,-,-,-
MYO7A_HUMAN,Q808K,0.112,-,-,-
MYO7A_HUMAN,Q809H,0.169,-,-,-
MYO7A_HUMAN,Q809K,0.174,-,-,-
MYO7A_HUMAN,Q809R,0.176,-,-,-
MYO7A_HUMAN,R811C,0.123,-,-,-
MYO7A_HUMAN,R814S,0.533,Altered Disordered interface (Pr = 0.47 | P = 3.8e-03); Altered DNA binding (Pr = 0.15 | P = 0.04); Altered Coiled coil (Pr = 0.13 | P = 0.04), ELME000012|ELME000134|ELME000137|ELME000173|ELME000202|ELME000233|PS00005,-
MYO7A_HUMAN,Q815G,0.182,-,-,-
MYO7A_HUMAN,Q815R,0.051,-,-,-
MYO7A_HUMAN,I817M,0.252,-,-,-
MYO7A_HUMAN,I817V,0.116,-,-,-
MYO7A_HUMAN,I818T,0.363,-,-,-
MYO7A_HUMAN,V843L,0.295,-,-,-
MYO7A_HUMAN,L855V,0.197,-,-,-
MYO7A_HUMAN,H856Y,0.221,-,-,-
MYO7A_HUMAN,Q857R,0.056,-,-,-
MYO7A_HUMAN,R860K,0.144,-,-,-
MYO7A_HUMAN,A861G,0.075,-,-,-
MYO7A_HUMAN,A918E,0.057,-,-,-
MYO7A_HUMAN,A918K,0.221,-,-,-
MYO7A_HUMAN,R921P,0.624,Altered Coiled coil (Pr = 0.53 | P = 6.5e-03); Loss of SUMOylation at K922 (Pr = 0.47 | P = 5.5e-04); Gain of Acetylation at K916 (Pr = 0.24 | P = 0.02), ELME000002|ELME000102|ELME000108|ELME000149,-
MYO7A_HUMAN,Q928R,0.167,-,-,-
MYO7A_HUMAN,V937I,0.030,-,-,-
MYO7A_HUMAN,G954A,0.090,-,-,-
MYO7A_HUMAN,R974Q,0.074,-,-,-
MYO7A_HUMAN,R975M,0.183,-,-,-
MYO7A_HUMAN,R975T,0.215,-,-,-
MYO7A_HUMAN,A984T,0.100,-,-,-
MYO7A_HUMAN,A1005S,0.228,-,-,-
MYO7A_HUMAN,H1029Q,0.584,Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Gain of Sulfation at Y1028 (Pr = 0.03 | P = 0.02), None,-
MYO7A_HUMAN,D1034N,0.723,, PS00008,-
MYO7A_HUMAN,I1045V,0.253,-,-,-
MYO7A_HUMAN,M1061I,0.185,-,-,-
MYO7A_HUMAN,K1067N,0.667,Altered Disordered interface (Pr = 0.31 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.02); Loss of Ubiquitylation at K1067 (Pr = 0.22 | P = 2.9e-03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000063|PS00005,-
MYO7A_HUMAN,Q1097P,0.386,-,-,-
MYO7A_HUMAN,P1099S,0.122,-,-,-
MYO7A_HUMAN,K1104R,0.085,-,-,-
